Lincoln Pharmaceuticals announced that its R&D (research and development) team successfully launched a cough syrup brand Namcold-DX, which contains Dextromethorphan Polistirex. This is an extended release, unique product of novel technology. Normal cough syrups are effective upto 3-4 hours, so in 24 hours the patient has to take the syrup 4 to 5 times. However, Namcold-DX is an extended release product, so the drug releases periodically and therefore the patient has to take only 2 doses during 24 hours.

Dextromethorphan Polistirex is a liquid oral suspension with advanced Pennkinetic delivery system. First, uncoated particles of Dextromethorphan are released rapidly in the stomach to provide immediate effect while Polymer-coated particles provide sustained release of Dextromethorphan in the intestine. Dextromethorphan, a centrally acting non-opioid antitussive, acts centrally by depressing the cough center in the medulla of the brain and therefore elevates the threshold for coughing. Its antitussive potency is nearly equal to that of codeine, the company said.

Namcold-DX is designed for all age group of patient above 4 years. The product is time tested and many trials have been done and it is approved by DCGI (Drug Controller General of India), the company said.

Lincoln Pharmaceuticals said it will get more benefit in the market out of this unique product and the bottom line will also improve.

Shares of the company gained Rs 1, or 0.87%, to settle at Rs 116. The total volume of shares traded was 496,807 at the BSE (Thursday).